What a Urinary Alkaliser Case Study Taught Me About Measuring HCP Engagement

By Deepika Rallapalli

When I started working on a urinary alkalizer case study, my first task was to understand the category and its prescribers. But the research raised a bigger question: once a pharma company engages those doctors, how should it judge whether its efforts are working?

That question became the connection between my category research and the prescription metrics I explored in my LinkedIn articles.

The work brought together three areas: understanding the HCP audience, defining useful measures, and presenting the findings in a way that helps a brand team make decisions.

Understanding the Doctors Behind the Numbers

My research mapped the urinary alkalizer category and relevant prescriber groups, including urologists, general physicians, nephrologists, and gastroenterologists.

This was the starting point for thinking about engagement. Before choosing a channel or developing content, a team needs to understand why a particular speciality is relevant to the category and what information its doctors may need.

I explored the broader changes in pharma communication in How HCP Engagements by Pharma Companies Are Evolving in 2025. For this case study, the practical question was how to apply that thinking to plan communications for specific prescriber groups.

Deciding What to Measure

The next question was how to evaluate engagement.

Doctor reach, email responses, webinar attendance, and representative interactions can help describe campaign activity. Prescription measures add another view: how products are performing and how prescribing patterns change over time.

In Prescription & HCP Engagement Metrics: A Key to Pharma Success, I outlined measures covering prescriptions, HCP engagement, representative productivity, prescriber segments, and educational programmes.

For the case study, these measures provided a way to connect audience planning with performance analysis. They also helped frame questions worth investigating:

• Are we reaching the prescriber groups we intended to reach?
• Which channels are receiving a response?
• How do prescription trends vary across products, regions, and specialities?
• Where do we need more information before recommending a change?

Looking at engagement and prescriptions together can reveal patterns. Determining whether an engagement caused a prescription increase takes further evidence.

Making the Findings Useful to Leadership

I then explored how to present the analysis to senior management.

My Monthly Rx Performance Snapshot used Power BI and sample data to show how prescription and engagement information could be organised by product, channel, geography, and speciality.

The purpose was to make the findings easier to discuss. A regional difference, for example, should prompt questions about coverage, market conditions, and execution. A channel with high engagement should be examined alongside its cost and the audience it reaches.

This is where the analyst’s interpretation matters. Leadership needs to understand what the figures suggest, what remains uncertain, and which action is worth considering.

Where ROI Fits

The work also led me to ask: What’s the actual ROI of our HCP engagement strategy?

When agencies report using different definitions and formats, comparing performance becomes difficult. Common measures and a consolidated view can help brand teams assess their activity more consistently.

Calculating financial ROI requires more: campaign costs, attributable returns, and a sound basis for connecting the two. The case study provides a foundation for that assessment by identifying what to measure and how to interpret it.

What the Project Demonstrates

The urinary alkalizer research gave the work its context. The Rx metrics gave it a measurement structure. The reporting exercise showed how the analysis could support a management discussion.

Together, they demonstrate how I approach a pharma marketing problem: research the category, understand the audience, define the measures, examine the data, and explain what the findings mean for the business.

The most useful outcome is a clearer basis for deciding what to investigate, what to improve, and where to focus resources.

Project note: The category research and prescriber mapping form the basis of the urinary alkalizer case study. The monthly Rx reporting example uses sample data from online sources. Its recommendations and forecasts do not represent verified campaign outcomes.

About the author

Deepika Rallapalli works across pharmaceutical marketing and business analytics, focusing on HCP engagement, prescription performance, and reporting that supports business decisions.

Core Keyword: HCP engagement analytics